Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: A preliminary study

Tokunaga, Yukihiko; Hata, Koichiro; Nishitai, Ryota; Kaganoi, Junichi; Nanbu, Hirokazu; Ohsumi, Kiyosi

doi:10.1002/(sici)1096-9098(199709)66:1<45::aid-jso9>3.0.co;2-n

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study on 55 patients compared the effects of sequential methotrexate (MTX; 100 mg/m 2 ) and 5-FU (600 mg/m 2 ) followed by LV rescue (treatment MFL), as an adjuvant chemotherapy, with a combination of MMC (12 mg/m 2 intraoperatively, then 6 mg/m 2 every other week after surgery for 2 months) and oral UFT (375 mg/m 2 /day) for at least 3 years. The overall survival and disease-free survival rates were significantly higher and the recurrence rate significantly lower in the MFL group, demonstrating the superiority of MFL therapy for improving postsurgical survival [184].…”

Section: Adjuvant Therapy In Colorectal Cancermentioning

confidence: 81%

Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review

2002

View full text Add to dashboard Cite

Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumors. 5-FU has antitumor activity against epithelial malignancies arising in the gastrointestinal tract and breast as well as the head and neck, with single-agent response rates of only 10%-30%. Although 5-FU is still the most widely prescribed agent for the treatment of colorectal cancer, less than one-third of patients achieve objective responses. Recent research has focused on the biomodulation of 5-FU to improve the cytotoxicity and therapeutic effectiveness of this drug in the treatment of advanced disease. As all the anticancer agents, 5-FU leads to several toxicities. The toxicity profile of 5-FU is schedule dependent. Myelotoxicity is the major toxic effect in patients receiving bolus doses. Hand-foot syndrome (palmar-plantar erythrodysesthesia), stomatitis, and neuro-and cardiotoxicities are associated with continuous infusions. Other adverse effects associated with both bolus-dose and continuous-infusion regimens include nausea and vomiting, diarrhea, alopecia, and dermatitis. All these reasons explain the need for more effective and less toxic fluoropyrimidines.In the first part of this review, we briefly present the metabolic pathways of 5-FU responsible for the efficacy and toxicity of this drug. This knowledge is also necessary to understand the target(s) of biomodulation.The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). The pharmacological principles that have influenced the development of these new drugs and our current knowledge of the clinical pharmacology of these new agents, focusing on antitumor activity and toxicity, are presented.The literature was analyzed until March 2002. This review is intended to be as exhaustive as possible since it was conceived as a work tool for readers wanting to go further. The Oncologist 2002;7:288-323 The Oncologist 2002;7:288-323 www.TheOncologist.com Correspondence: M. Malet-Martino, Ph.D., Groupe de RMN Biomédicale, Laboratoire des IMRCP (UMR CNRS 5623), Université Paul Sabatier, 118, route de Narbonne, 31062 Toulouse Cédex, France. Telephone: 33-561-556271; Fax: 33-561-557625; e-mail: martino@chimie.ups-tlse.fr Received January 24, 2002; accepted for publication April 5, 2002. ©AlphaMed Press 1083-7159/2002 The Oncologist ® LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Define the main oral prodrugs of fluorouracil.2. Know the indications of the new oral prodrugs of fluorouracil.3. Review the main toxicities and drug interactions of oral prodrugs of fluorouracil.4. Evaluate the benefit(s) of using an oral prodrug of fluorouracil compared with classical treatments.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME by guest on http://theoncologist.a...

show abstract

Section: Adjuvant Therapy In Colorectal Cancermentioning

confidence: 81%

Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review

2002

View full text Add to dashboard Cite

show abstract

“…She underwent a total of 14 treatments of arterial infusion chemotherapy using 5-fluorouracil (5-FU) 1000 mg/ body, and 6 treatments of sequential methotrexate, 5-FU, and leucovorin regimen systemically for the 3 months following surgery. 3 Because cutaneous me-166 tastasis and lung metastasis developed, despite this chemotherapy regimen, she was started on a regimen of 5-FU, leucovorin, and cisplatin. She is alive at home with recurrence of the tumor.…”

Section: Case Twomentioning

confidence: 99%

The Incidence of Colorectal Cancer During Pregnancy in Japan: Report of Two Cases and Review of Japanese Cases

et al. 1998

Self Cite

View full text Add to dashboard Cite

Colorectal cancer during pregnancy is very rare. We report two additional cases of rectal carcinoma. A 34-year-old woman with an obstructive adenocarcinoma of the rectal region was diagnosed at labor. A 35-year-old woman with an adenocarcinoma of the rectal region was diagnosed at 32 weeks of gestation and underwent a cesarean section and rectal resection at 35 weeks of gestation. A retrospective review of the Japanese literature was performed to identify patients who appeared to have primary colorectal cancer during pregnancy. Thirty-six patients with colon cancer (75.0%), 10 (20.8%) with rectal cancer, and two (4.2%) of unknown sites have been reported in Japanese series. The average age of the mother was 32.2 years. The calculated incidence of colorectal cancer among Japanese pregnant women was one case per 502,316 live births during the years between 1986 through 1995. Although the majority of colorectal cancers diagnosed during pregnancy are rectal carcinomas, the patients in Japan were predominantly complicated by colon cancer. The fetal risk seems small, because there were no cases of colorectal cancer metastatic to the products of conception.

show abstract

Colon cancer during pregnancy

Cappell

2003

Gastroenterology Clinics of North America

View full text Add to dashboard Cite

Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: A preliminary study

Cited by 3 publications

References 13 publications

Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review

Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review

The Incidence of Colorectal Cancer During Pregnancy in Japan: Report of Two Cases and Review of Japanese Cases

Colon cancer during pregnancy

Contact Info

Product

Resources

About